Positron Emission Tomography in Breast Cancer

Diagnostics

Jose Luis Vercher-Conejero²  Laura Pelegrí-Martinez⁴  Diego Lopez-Aznar³  María del Puig Cózar-Santiago¹ 

[1] Department of Nuclear Medicine, General University Hospital-ERESA, Valencia 46018, Spain; E-Mail:;Clinical Area of Medical Imaging, Department of Nuclear Medicine, GIBI230, Polytechnic and University Hospital La Fe, Valencia 46026, Spain;Department of Nuclear Medicine, Provincial Hospital Consortium, Castellón de la Plana 12002, Spain; E-Mail:;Diagnostic Imaging, Sant Joan Despí Moisès Broggi Hospital, Sant Joan Despí, Barcelona 08970, Spain; E-Mail:

关键词: FDG-PET;    PET/CT;    PET/MRI;    breast cancer;    dedicated breast PET;    non-FDG radiopharmaceuticals;   

DOI  :  10.3390/diagnostics5010061

来源: mdpi

【 摘 要 】

Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography, or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, it reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in making the diagnosis of the disease at an early stage but also in enabling personalized therapy for patients with breast cancer.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.